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Cardiovascular disease (CVD) is currently the leading cause of death in U.S. women. As
of 2011, CVD events account for 52.8% of among this population (Heart Disease and Stroke,
2012). A greater portion of women die from cardiac death related to CVD prior to arrival to the
hospital (52%) then men (42%) (Shaw, 2009). Cardiac related deaths in women still remain one
of foremost public health concerns. These statistics in the female population have remained
consistently high while those of male counterparts are shown to be decreasing (Shaw, 2009).
According to major U.S. healthcare organizations such as the American Heart
Association (AHA), the Center for Disease Control (CDC), and the World Health Organization
(WHO), CVD is considered to be the number one healthcare topic of healthcare related
concern these days. CVD encompasses multiple symptoms and disease processes contributing to
debilitating morbidities and fatal outcomes. Including of, but not limited to, coronary heart
disease, hypertension, congestive heart failure, and stroke. Another concern emerging is the
consequences of cardiovascular disease in the female population.
Commonly considered by most to be a disease process characterized by male prevalence
with stereotypical symptoms, there are many varying factors concerning women and CVD.
These factors are evolving trends and could guide decisions of healthcare providers in treating
female patients as a separate entity. Thus promoting the most health merited benefits of therapy
and treating existing disease effectively. Females exhibit difference in vasculature structure,
endocrine changes, and responsiveness to medications that adversely affect structure and
integrity of a finely balanced circulatory system, when compared to their male counterparts.
Shared risk factors and these variances for men and women could potentate these risk factors and
lead to higher threats of morbidity and morality among the female population. These combined
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factors in conjunction with atypical symptom presentation often lead to misdiagnosis and under
treatment, permitting CVD to remain the leading cause of death in women.
Cardiovascular Disease in Women: The Differences in Genders
Cardiovascular disease is an umbrella term used to encompass many diseases of the
vascular system. Including, but not limited to, coronary artery disease, myocardial infarction,
stroke, and hypertension. Top healthcare organizations such as WHO, CDC, and AHA consider
these disease processes to be the number one health disparity and cause of mortality in today’s
society overall as well as specifically in women. These diseases are also a heavy financial pull
on the healthcare system with the resulting treatment, rehabilitation and missed wages. Based on
statistics from the AHA in 2009, CVD accounted for 236.1 per 100,000 deaths. That breaks
down to a rate of 2150 deaths per day from CVD; or one death every 40 seconds (Statistical Fact
Sheet Update, 2013). When evaluating heart disease specifically, it is still determined by the
healthcare community, to be the number one killer in both men and women (Heart Disease Fact
Sheet, 2012). CDC 2009 statistics, heart disease accounts for approximately 600,000 deaths
annually, that is one death every minute from heart disease (Heart Disease Fact Sheet, 2012).
The National Conference of State Legislatures attests that treatment for cardiovascular diseases
accounts for nearly $1 of every $6 spent on health care in the United States. In 2010, an
estimated $444 billion was spent on CVD, treatment, medication and lost productivity from
disability.
In reviewing the impact CVD has on the female population, the mortality rates are much
higher in females. Even though a higher percentage of males suffer from CVD insults, the
mortality rates are higher in the female population from the effects (Shaw, 2009). One in three
females has some form of cardiovascular disease (AHA, 2013). CVD has claimed the lives of
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401,495 women in 2009. Compare this to 270,865 deaths caused by all combined cancers,
making CVD accountable for 51% of deaths of this cohort (Statistical Fact Sheet, 2013).
The Women’s Ischemia Syndrome Evaluation (WISE) study sponsored by the National
Institute of Health (NIH) made significant discoveries in gender specific differences. These
differences include; the pathophysiology of CVD processes, anatomy involved in this disease
process and responses to therapies provided for the prevention and treatment of CVD and
presenting symptoms (Finks, 2010). These differences can lead to significant consequences from
failure to acknowledge the variances and treat accordingly.
The question addressed through this literature review is; if there is a measurable decrease
in the number of deaths overall from CVD, leading to the belief that there are effective
screening, identification and treatment of risk factors, why is there not a same measurable
reduction in the number of women as an identifiable population suffering from CVD and heart
disease (HD)?
Can men and women demonstrating risk factors or current disease processes of CVD be
grouped together in the same assessment and treatment category, or are there definitive
differences in the populations which would warrant distinguished assessment and treatment
algorithms based on gender. In addition, are the commonly used treatment options beneficial to
women who are at an increased risk of mortality and morbidity, and can this confirmed by
current statistical research?
The purpose of this literature review is to: evaluate the current screening methods used to
identify risks for CVD, and determine the effectiveness of therapy commonly prescribed in
treatment of as women with this disease(s). Thus enabling providers to better manage these
women at risk for CVD and prevent further progression into a higher risk category. Outcomes of
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better therapy, including primary, secondary, and tertiary therapy, show effective measurable
results of reducing incidence of CVD in women.
The framework used to guide this study was the Neuman’s systems model. In preventing
CVD in women, the three levels of prevention should be used to guide providers in optimal CVD
therapy benefits. Primary prevention is determining a woman’s potential for risk factors and
promoting education on prevention of these risks. Secondary prevention would be effective
screening and treatment of current risk factors and current disease processes in order to avoid
progressing into a high level of risk. Tertiary prevention includes treatment of morbidities
resulting from a CVD effect, and prevention of complications of further disease progression.
Within the Neuman’s model there are variables which must be incorporated into
treatment and prevention in women. These include; the physiological structure and function of
the body, the mental processes and relationships, the sociocultural and spiritual variables, and
overall development. There are also known and measurable stressors as well as unknown and
unforeseen stressors which can disrupt or change a balance in the variables, altering the
effectiveness of outcomes of research or treatment therapy. All these play a role in deciding
effective preventative measures, assessment techniques and treatment options.
In conducting this literature review, criteria in searching for articles included the phrases;
women and cardiovascular disease, women and heart disease, heart disease and gender
differences and cardiovascular disease. Articles were then chosen based on relevance to the
topic of cardiovascular disease, inclusion of gender analysis and a patient population of more
than 100 participants. No articles older than 2002 were included in this review in efforts to keep
with the more up to date and accurate research within the previous 10 years. Statistical data
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incorporated into this review was retrieved from credible healthcare organizations, including the
CDC, WHO and AHA, from the year 2009 to present.
In shaping the underlying foundation in dissimilarity of the pathophysiology,
presentation, risks for, and treatment of CVD in women, defining the potentials of these
variations is vital. Once the root, or roots, for variation is discovered and established, it is
necessary to evaluate treatment options commonly used. Then decide their benefit verses
vulnerability in treating the female population at risk for or recovering from CVD. A secondary
goal of this review is to raise awareness in providers to educate their women patients on their
risk factors, both modifiable and non-modifiable, for CVD as well as the consequences of this
disease and available optimal treatment methods.
Mosca, Manson, Sutherland, Langer, Manolio, et al, (2009), found that through education
and raising awareness of the risk of CVD to women, there was a heightened awareness of
individual risk and a sense of ownership of protecting one’s health from those risk factors. The
Heart Truth campaign initiated in 2001 is sponsored in the United States by the National Heart,
Lung, and Blood Institute, more commonly known as the “Red Dress” campaign, which was
designed to help raise public awareness of the risks of CVD knowledge and awareness of leading
cause of death among women. This campaign hoped to lead an increase in public education and
also evaluate the current public knowledge regarding CVD. Efforts of this campaign continue
today, gaining popularity and raising awareness of the health disparities of CVD. Presently 55%
of surveyed participants correctly identified heart disease as the leading cause of death compared
to 30% in 1997 (Mosca et al., 2009). Before this public campaign effort there was a lack of
discrepancy between the risk of men and that of women as CVD which was considered by the
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public as a male population disease, and was studied and treated according to outcomes within
this male population based research.
Oliver-McNeil and Artinian (2009) demonstrated that 93% of surveyed participants,
although knew they had some risk for CVD, were not aware of their individual risk and what
they could do to lower their risk of potentially suffering the effects of CVD. Worrall-Carter, Ski,
Scruth, Cambell, & Page (2011) found that in the female population, most risk factors are
modifiable and are simply overlooked or underestimated by providers and public alike.
According to their study, women are often underrepresented in trials in identifying and treating
risk factors. The highest risk factors associated with CVD in women were diabetes mellitus,
smoking, and hypertriglyceridemia, (Worrall-Carter et al, 2011). These risks are all modifiable or
preventable, meaning they are improvable and in turn, if treated appropriately, could lower the
risk of a future CVD event (Worrall-Carter et al, 2011). However Mosca et al, (2009) found that
more often than not, women were deemed by providers to be at low risk for CVD, therefor were
under identified for these risk factors and not treated effectively to prevent further progression of
CVD.
There was a lack of determining women with potential of developing CVD by healthcare
providers, despite demonstrating the same risk factors listed as culprits by standardized national
healthcare organizations. Physician awareness of three national CVD prevention guidelines
(NCEP ATP III, JNC 7 and AHA) differed by specialty of practice; Family Practice, Obstetrics
and Gynecology, and Cardiology. The rate of highest identification of potential CVD disease in
the patient population was that of cardiologists (80%) although it was still not comparable to the
rate of identification of CVD in the male population by cardiologists (95%). Rates of
recognition lowest among OBGYN (58%), although their specialty is caring for the female
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population, including women suffering with high risk cardiovascular processes such as eclampsia
and pregnancy induced cardiomyopathy. Physician incorporation of therapy guidelines for
women were again highest among cardiologists (59%) followed closely by PCPs (46%). The
least likely to employ the guidelines for therapy were OBGYN physicians who specifically
treated women (24%) (Mosca, Linfante, Benjamin, Berra, Hayes, et al., 2005).
In reviewing the pathophysiological differences of women in reference to CVD, Shaw
(2009) determined women to have less anatomical and obstructive coronary disease (<50% of
women with symptoms of cardiac disease), but found to have higher rates of ischemic disease,
with a relatively preserved left ventricular function. This study also found this to contribute to
women having an increased overall CVD mortality compared to similarly aged males. “The
WISE study implicates abnormal coronary reactivity, microvascular dysfunction and plaque
erosion with distal microembolization as female specific ischemic heart disease
pathophysiology” (Shaw, 2009)
More than half of these women undergo repeated hospitalizations with signs and
symptoms of heart ischemia without objective findings such as coronary artery disease. Thus
leading Shaw (2009) to determine heart disease prevalence in women to be predominately
ischemic heart disease (IHD) (Shaw, 2009). These findings limit conventional treatment
measures, such as cardiac catherization or coronary bypass grafting from preventing the
occurrence of mortality and morbidity from heart disease such as myocardial infarction, direct
cardiac hypoxia, or atherosclerotic disease. A study of female sex as an independent predictor of
survival and morbidity was conducted by Ahmed, Tully, Knight, and Baker (2011) who included
a gender differential of their results from a study of 4,742 participants (23% of which were
female) with a 7.9 year median follow up from receiving coronary artery bypass grafting
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(CABG). The authors discovered that the women who suffered cardiac injury, despite receiving
CABG, were associated with early morbidity and long-term cardiac mortality. They also note
that more female participants were older in age, carried higher numbers of concomitant
morbidities. Prior to undergoing coronary artery bypass grafting were already with greater
proportion of cardiac risk factors once patients were identified to be in need for bypass grafting
(Ahmed, et al., 2011).
Grines (2012) discussed the outcomes of women who presented for cardiac
catheterzation, verse men in cardiac catheterizations with stent placement, and were older and
with more comorbidities then men. Women were also at a higher risk for mortality after cardiac
catheterization which was not consistently eliminated after adjustments for comorbidities.
Women were also found to be at a higher risk for bleeding, incomplete revascularization and
failure to deploy stent second to smaller coronary arteries (Grines, 2012).
So this raises the question; are there are specific female risk factors for CVD related to
the circumstance of being of the XX gene as opposed to the XY gene or is it simply a matter of
under education and treatment initiation by providers to a population at risk as the previous
studies listed have demonstrated that leads to this health care crisis?
In reviewing some female specific issues concerning CVD, Miller & Best (2009) states
that “the lack of attention to sex differences in etiology of cardiovascular disease has resulted in
inadequate methodologies and strategies to prevent, diagnose, and treat cardiovascular disease in
women compared to that in men.” In reviewing sex disparities in associated risks of CVD, the
authors review three categories of risks; conditions unique to one sex such as menopause and
pregnancy induced hypertension in women, conditions which can occur in both sexes, and
conditions that are occurring to both sexes but present differently per gender. Through their
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research presentation, the authors emphasize the importance in the need for the developing a
valid assessment tool for use, which will incorporate information regarding not only the risk
factors found in both genders, but with given attention to reproductive history including hormone
therapy, menopause, pregnancy exposure and complications or risks within the reproductive
years which may contribute to a increased risk of developing CVD.
There has been a great deal of controversy over the role played by hormone therapy in
relation to the progression of risk in CVD events and whether or not estrogen therapy is indeed
beneficial in preventing these events. Or whether the risks associated with the therapy outweigh
what benefit there may be. Miller (2010) found that sex steroids affect all components of the
vascular wall, heart, as well as blood elements which come in contact with luminal surfaces of
the vascular system. Once these hormonal levels are altered, the vasculature system becomes
vulnerable to adverse effects of this change. This includes but not limited to poor vascular
contractibility which can result in consistently constricted vessels, or thinning of luminal wall
making the vessel exposed to damage. Estrogen was noted to carry a high role in the vascular
dilation in premenopausal women by endothelium-dependent vascular relaxation through nitric
oxide (NO), prostacyclin, and hyperpolarization pathways (Orshal & Kahlil, 2013). However,
clinical trials such as the Heart and Estrogen/Progestin Replacement Study (HERS), HERS-II,
and the Women's Health Initiative did not support the experimental findings and instead
demonstrated adverse cardiovascular events of hormone therapy (HT) in aging women such as
vascular embolization and heart failure. The lack of vascular benefits of HT may be related to
the hormone used, the estrogen replacement, or the patient's particular cardiovascular condition
or age (Qiao, McConall & Kahlil, 2008). These studies suggest not necessarily the need for
HRT in order for vascular protection, but early identification and proper treatment in regards to
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hypertension is the most beneficial form of CVD prevention and therapy for postmenopausal and
premenopausal female patients.
Another area found to be at specific increased risk for the female patient was
hypertriglyceridemia and diabetes mellitus. A Canadian led global INTERHEART standardized
case-control study was conducted that measured the nine greatest risk factors for CVD. This
study screened all patients admitted to the coronary care unit or equivalent cardiology ward for a
first MI at 262 participating centers in 52 countries. Through this study it was determined that
hypertriglyceridemia was an independent risk factor in determining a female risk for heart
disease (O’Riordan, 2004). Diabetes mellitus (DM) was identified as having the greatest
difference for developing CVD, placing women with DM at a 3-4 fold increase of developing
CVD in comparison to women without DM (Worrall-Carter, et al., 2011). Matthews, Crawford,
Chae, Everson-Rose, Sowers, et al. (2009) also concluded through their study that there was a
measurable substantial increase in total cholesterol and low density lipoprotein (LDL) at the time
of final menstrual period (FMP). Although the relationship between estrogen and lipid
regulation is not completely understood, it stands to hypothesize that physiologic levels of
estrogen are known to help maintain favorable lipoprotein profiles in women. Once a women
enters menopause and the levels of estrogen rapidly declining, levels of high density lipoprotein
(HDL)-cholesterol decrease while triglyceride levels and well as LDL- cholesterol levels begin
to rise. A low HDL-cholesterol level is a strong forecaster of increased risk of CVD in women.
The average HDL cholesterol level in moderately healthy adult women is 55 to 60 mg/dL. A
decrease in HDL cholesterol level of 10 mg/dL increases overall coronary disease risk by an
estimated 40 to 50 percent.
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When evaluating treatment through pharmacological therapy for women, it was noted
there was several treatment algorithms in which women either benefited or did not benefit in
therapy at all in comparison to men or the average measured statistics. Walsh and Pigone, (2010)
reviewed the most common medical management and the difference in effects on patients in
regards to gender. In men there was a definite reduction of CVD events with preventative
pharmacological therapy, regardless of the deemed level of risk. In women being treated with
the same preventative pharmacological therapy, there was only a minimal reduction of risk
within categories of women deemed to be a moderate to higher risk of CVD. An individual level
of risk is determined by presence of current risk factors. This includes current presence of both
modifiable and non-modifiable such as genetics, treatment and compliance with the treatment
goals, as well as current presence of disease which exacerbates CVD such as hypertension,
hyperlipidemia and diabetes. These factors are all used to assess and determine a person’s risk
for developing or experiencing a CVD occurrence when considering initiation of
pharmacological therapy.
Lipid lowing pharmacological therapy initiated in women patients with hyperlipidemia,
defined as an increased level of serum cholesterol and triglycerides, was found to reduce
incidence of CHD by 50% (Mosca, et al., 2009). Use of these agents in women without a
demonstrated case of CVD, although a reduction in CHD events was determined, there was not a
proven reduction in overall CVD mortality. In women with known CVD, use of antihyperlipidemia medications found a decrease in more CHD events and associated mortality
(Walsh & Pigone, 2004).
In evaluating antithrombotic therapy, women were found to be at a disadvantage with the
pharmacological treatment. Aspirin therapy affects women differently than men as deduced
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through a study by Xhyheri & Buliardini (2010), finding that aspirin is more effective in
preventing a MI in men (32%), but decreased stroke risk in women (17%). Plavix was found to
be less effective in reducing the risk of a CVD event in women (7%) then men (16%) while
therapy was associated with an increased risk of bleeding in women (43%) then men (22%).
Hypertensive therapy is also complicated in women as earlier discussed by the loss of sex
steroids in post-menopausal women, reducing the vasodilation response of the vascular system.
Traditional treatment options studied by Xhyheri & Bulgiardini (2010), which were used for post
therapy after a cardiovascular event, was determined to have a different effect on women. ACE
inhibitors used in post recovery from MI or CHF events was shown to have less effectiveness in
women (22%) then men (37%). Beta blockers were found to be more effective in women (31%)
then in men (5%).
Through the research conducted for this review, it was noted that multiple articles either
cited or demonstrated the lack of female participants within the current research regarding the
study of risks of developing CVD, as well as the treatment, and consequences of CVD. Many
reasons for this lack of inclusion were listed including, risk of injuring a fetus by including
women of child bearing age, altering fertility abilities, variability in data results by incorporating
women undergoing hormone therapy, or lack of participants by failing to recognize pertinent risk
factors or symptoms for research inclusion. Worrall-Carter cited that not only women were
underrepresented in CVD prevention and treatment trials (30%) nut were not represented
properly as most women included were statistically older with more comorbidities then the male
counterparts. There was also a under representation of gender differences in research studies.
Only one-third of studies evaluated cited these gender specific findings. This leads most

CARDIOVASCULAR DISEASE IN WOMEN

14

outcome based treatment theories being predominately geared towards a male population
(Worrall-Carter, et al., 2011).
The Framingham study is considered a landmark research study, as it incorporates the
female population individually as well as gives particular details to the risk assessment, treatment
and trending details about cardiovascular disease in women. According the Framingham
website, they state:
“Since our beginning in 1948, the Framingham Heart Study, under the direction of the
National Heart, Lung and Blood Institute (NHLBI), formerly known as the National
Heart Institute, has been committed to identifying the common factors or characteristics
that contribute to cardiovascular disease (CVD). We have followed CVD development
over a long period of time in three generations of participants.”
(Framinghamheartstudy.org).
This study is currently ongoing, presently in the fourth generation of study, and focuses
on using the data collected to the development, progression, and effects of treatment of
cardiovascular disease. Over the years, careful monitoring of the Framingham Study population
has led to the identification of major CVD risk factors. This study contributes valuable
information on the effects of these risk factors, such as blood pressure, blood triglyceride and
cholesterol levels, age, gender, and psychosocial issues in the development of CVD in women.
This landmark research raised awareness to there being a prevalent gender difference in regards
to CVD. Risk factors for other physiological conditions in women, such as dementia, have been
and continue to be investigated. In addition, the relationships between physical traits and genetic
patterns predisposing women the CVD processes are continued to be studied
(Framinghamheartstudy.org).
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In exploring the literature in this study, there is a definite difference in the process of
identifying CVD in women and ideal treatment therapy. The research determined not only is
there a lack of identification by providers of women presenting with risk factors, there is
suboptimal therapy initiated if any therapy prescribed at all. This deficiency of healthcare to a
population at risk is contributing to a failure in declining the statistics of morbidity and mortality
of women, as well as using a great deal of healthcare dollars on highly preventable disease. In
treatment of the disease process encompassed in CVD, there is a need for a sex based screening
and gender based treatment algorithm for providers.
Increasing public awareness of this issue would raise knowledge of risk factors to those
demonstrating these threats which in turn would possible, prompt further cessation of risk.
Promoting behavior through a sense of health conscious ownership as well as encouraging
women to discuss concerns with their healthcare providers.
The limitations of this study are the lack of substantial gender based data. There is a
consistent acknowledgement of a lack of women participants or gender distinction in studies or
reviews conducted. Even with the inclusions of the available data for gender discernment in
these trials, there was a definite greater participation of men which leads to question the validity
of the results from these trials. The Framingham study which was created in effort to include
women and gender differences over a period of generations acknowledges the lack of female
participants. There needs to be more focused research on the adequate treatment of CVD as it
pertains to female population well as reducing the risk of developing high risk probability of an
event and providing pertinent education to the patients in reducing their risk. Development of a
gender based assessment and treatment algorithm. If available to providers, it would be
beneficial in identifying a women’s tendency to developing CVD as well as prime treatment
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therapy to decrease her risk of suffering the effects of this disease process. This in turn could aid
in decreasing the devastating statistics currently plaguing the women of America today.
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Appendix

Design and Purpose

Population (N)

Intervention/Interpre
tation

Findings

Oliver-McNeil, S., Artinian,
N. & Beaumont, W. (2002).
Women’s Perceptions of
Personal Cardiovascular Risk
and Their Risk-Reducing
Behaviors. American Journal
of Critical Care, 11, 221-227.

Descriptive study
conducted at a 925-bed
teaching hospital to
describe perceptions of
cardiovascular risk factors
and risk-reducing
behaviors among women
patients newly diagnosed
with cardiovascular
disease.

33 women > 18
years or older with
CAD diagnosed with
angiographic
findings or
confirmation of a MI
within the preceding
7 days

SPSS descriptive
statistics were used to
analyze all study
variables and the
research questions.

This study concluded that
women included had limited
awareness of their personal
risk limiting their ability to
participate in CHD
prevention
Documented risk factor in
medical records did not
correlate with patients
perceived risks, however did
correlate with the AHA
cardiovascular risk factors
excluding body mass index
and life stress

Mentally competent
as evidences by
living independently
in the community,
no prior history o
Cad and able to read
and write english

Despite 93% of participants
knew they had some risk for
CAD, they were unaware
they had multiple risk
factors or the impact these
risks held for their overall
health

Mosca, L., Mochari, H.,
Christian, A., Berra, K.,
Taubert, K., Mills, T., et al.
(2006). National Study of
Women’s Awareness,
Preventive Action, and
Barriers to Cardiovascular
Health. Circulation, 113, 525534.

A meta-analysis study
conducted through surveys
to determine the current
knowledge of
cardiovascular disease in
public women.

1485 women >25
years of age
completed the
survey.
A total of 18905
calls were made to
include the number
of volunteer
participants.

.Statistical analysis of
the data was completed
using SPSS.
Logistic regression
models were used to
determine knowledge
of variables.
X2 analysis was used
to determine the
association of
perceived risk and
defined risk.

There was no identified
relationship between risk
identification and riskreducing behaviors.
55% correctly identified
CVD as the leading cause of
death compared with 30% in
1997 (P<0.05) 63.1% of
cited CVD as the leading
cause of death in men.
Awareness among women
who considered themselves
at an increased risk
(moderate or high) was
higher then women who
perceived themselves to be
at a lower risk (59.4% vs
60.9% vs 49.0%)
81% of women said they had
heard or read about the
prevalence of heart disease
in the past 12 months. These
women were more likely to
be aware of CVD as the
leading cause of death in
women (68.9% vs 51.2%;
P<0.0001)
88% confirmed they had
yearly checkups with their
healthcare provider. 54%
said their healthcare provider
discussed their risk factors
for CVD.
Overall statistics showed the
women who were more
aware of the risks for CVD
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Cardiovascular Disease in
Women. Primary Care Clinic
Office, 36, 73-102.
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deemed themselves at a
moderate to high risk level.
These women were more
proactive in decreasing their
risk factors then those
women who considered
themselves at low risk.
CVD affects women
disproportionately then it
does men as it is diagnosed
less frequently, treated less
effectively, and carries a
higher mortality rate in
women. Today CVD affects
42.1 million women (36.6%
of the female population)
and accounts for 41.3% of
all deaths of American
women.

This descriptive study was
conducted to discern the
gender specific differences
in the physiology,
presentation of symptoms’
and treatment of
cardiovascular disease

The cost of healthcare for
CVD in 2005 was projected
at $394 billion: $242 billion
in direct healthcare costs and
$152 billion in lost
production and wages.
The lifetime risk for CVD in
2 in 3 for men and 1 in 2 for
women. Annual rates of first
major CVD event for
women track those of men
but are delayed by 10 years.
In persons younger the 75
years of age, more CVD
events occur in men because
of CHD than women,
whereas more CHF events
occur in women than men.
There are less “common”
presentation symptoms of
CVD/CAD in women than
in men which often lead to a
misdiagnosis.
The lifetime risk of dying
from a stroke is twice that of
men (16% vs 8%)
Two thirds of sudden deaths
in women occurred in
women without and history
of symptoms whereas only
50% of men were similarly
affected.

Vaid, I., Wigington, C.,
Borbely, D., Ferry, P. &

This open cohort study
design assesses and

WISEWOMAN
began in 1993 to

The current (4th) phase
of WISEWOMAN

Women have a higher
incidence of death in the first
year after a heart attack then
men (38% compared to
25%), twice as likely as men
to die after bypass surgery, a
higher rates of disability due
to heart failure within 6
years after a MI (46% to
22%)
Women with low income
endure a disproportionate
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Manheim, D. (2011).
WISEWOMAN: Addressing
the Needs of Women at High
Risk for Cardiovascular
Disease. Journal of Women’s
Health, 20(7); 977-982.

discusses the finding of the
WISEWOMAN study
program.

Wenger, N. (2012). Women
and Coronary Heart Disease:
A Century After
Harrick:Understudied,
Underdiagnosed and
Undertreated. Circulation,
126, 604-611.

A primary study of
descriptive design to
discuss the current status
of studies of CHD in
women from 1992-2012
including the challenges
met with these studies and
the proposed treatment
outcomes hypothesized.

Mosca, L., Linfante, A.,
Benjamin, E., Berra, K.,
Hayes, S., Walsh, B., et al.
(2005). National Study of
Physician Awareness and
Adherence to Cardiovascular
Disease Prevention
Guidelines. Circulation, 111,
499-510.

Online cross-sectional
survey including case
studies to assess
knowledge of screening,
preventative and
interceptive therapies and
tools
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extend preventative
health services
offered to women
who participated in
the National Breast
and Cervical Cancer
Early Detection
Program
(NBCCEDP).

supports grantees in
developing partnerships
that will bring about
policy, environment,
and system changes in
efforts to support heart
healthy behaviors.

impact of the burden of
CVD resulting from limited
access to healthcare resulting
from being uninsured or
limited financial means.

Lack of public awareness of
CHD in women in risk
determination, symptom
presentation, screening
techniques, diagnostic
procedures, and sex
disparities in application of
evidence based therapies
contribute to poor CHD
outcomes.

500 randomly
selected physicians
(300 primary care,
100 OB/GYN, 100
cardiologists) drawn
from the J. Reckner
Associated database

Descriptive statistics of
physician practices and
preventative
recommendations were
presented as
proportions

Despite CVD burden,
women remain
unrepresented in clinical and
are at a disadvantage by
absence of sex –specific
analysis.
Physician awareness of 3
national CVD prevention
guidelines (NCEP ATP III,
JNC 7 and AHA) differed by
specialty of practice
Physician recommendations
about lifestyle interventions,
supplements, and aspirin
therapy were sub optimal
among low-risk patients
across the specialties
Supplements were more
highly recommended among
the mid to high risk
populations

Mochari-Greenberger, H.,
Mills, T., Simpson, S. &
Mosca, L. (2010).
Knowledge, Preventive
Action, Barriers to
Cardiovascular Disease
Prevention by Race and
Ethnicity in Women; An
American Heart Association
National Survey. Journal of
Women’s Health, 19(7): 12431249.

Survey using standardized
questionnaire about
knowledge of healthy risk
factor levels, preventative
actions and barriers to
preventative actions.
The purpose of this study
was to assess differences in
CVD knowledge,
preventative actions, and
barriers to prevention by
racial/ethical group in a
nationally representative

1008 women >25
years of age with at
least one person
living in their
household or one
person not living in
their household for
whom they made
healthcare decisions
for

Descriptive statistics of
respondents’
characteristics,
knowledge level,
preventative actions
and barriers to these
actions were evaluated
between the ethnic
groups.

Results for correctly
identifying risks for patient
populations considering
gender difference were
similar across the specialties.
Women risks were identified
less often than that of males.
Women were also more
likely to be assigned to a low
risk category despite being a
similar calculated risk as
men
Knowledge that CHD is the
leading cause of death varied
by racial/ethnic groups
which were independent of
age, marital status,
education, employment,
income level or having
children
Hispanic populations was
more likely to be unaware of
the correlation between
blood pressure and CVD
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sample of women.

Heidenreich, P., Trogdon, J.,
Khavjou, O., Butler, J.,
Dracup, K., Ezekowitz, M., et
al. (2011). Forecasting the
Future of Cardiovascular
Disease in the United States:
A Policy Statement From the
American Heart Association.
Circulation, 123, 933-944.

A case study using
primary, secondary studies
randomized and controlled
studies to forecast the
future costs and national
effects needs for treating
cardiovascular disease
from the year 2010 – 2030.
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Blacks and Hispanics were
less likely than
Caucasian/other groups to be
aware that lipid levels were
in correlation with the risk of
CVD
Race/ethnicity was not
associated with the risk of
increased fasting blood
glucose levels in relation to
CVD, although those
respondents with <4 years of
college education were 25%
less likely to know optimal
fasting blood glucose level
CVD is responsible for 17%
of national health care
expenditures and expected to
increase as the population
ages.
By 2030 – 40.5% of the US
population is predicted to
have some form of CVD.
People >65 years of age is
determined to have a higher
prevalence of CVD, and this
population segment is
expected to grow
significantly over the next
two decades.
Between the years of 20102030, projected healthcare
costs for treating CVD is
forecasted to triple from
$273 billion/year to $818
billion/year.

Shaw, L., Bugiardini, R. &
Merz, N. (2009). Women and
Ischemic Heart Disease.
Journal of the American
College of Cardiology,
54(17): 1561-1575.

This study was a crosssectional design conducted
to evaluate the authors
given hypothesis that
women experience more
adverse outcomes
compared with men in the
treatment of CAD because
obstructive CAD remains
the current focus of
therapeutic strategies.

Indirect costs such as lost
wages due to CVD disease is
projected to increase by 61%
(from $172 billion in 2010 to
$276 billion in 2030.
Cardiac death remains the
leading cause of death in
women of all ages.
Women have less anatomical
obstructive CAD yet greater
rates of myocardial ischemia
and mortality compared with
similarly aged males.
Contributing factors to
higher female ischemic
cardiac rates include
abnormal coronary
reactivity,
microvascularization
dysfunction, and plaque
erosion, and distal
microembolization .
A greater proportion of
women die from sudden
cardiac death prior to arrival
at the hospital (52%
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compared with 42% of men).
More than 80% of midlife
women have 1 or more
traditional cardiac risk
factors.

Gleeson, D. & Crabbe, D.
(2009). Emerging Concepts in
Cardiovascular Disease Risk
Assessment: Where do
Women Fit In? American
Academy of Nurse
Practitioners, 21, 480-487.

The purpose of this review
of literature was to
determine and highlight the
limitations in the
assessment of women and
discuss the current
information in the process
of assessment of risk
factors in the female
patient population, the
pitfalls of these processes
and the role these risk
factors play in CVD.

Over half of symptomatic
women without obstructive
CAD continue to have
symptoms and undergo
multiple hospitalizations and
testing which result in
diagnostic and therapeutic
uncertainty.
Use of oral contraceptives in
conjunction with smoking is
associated with a significant
risk of developing
thrombosis and CVD
complications.
The mortality among males
with diabetes is twofold
higher, and fourfold higher
than the general population
for CV illness.
Women have a one in six
chance of developing heart
failure from hypertension
etiology while men have a
one in nine chance.

Douglas, P. & Poppas, A.
(2012). Determinants and
Management of
Cardiovascular Risk in
Women. UpToDate.
Retrieved January 12, 2013
from www.uptodate.com

Literature review to
identify the clinical
presentation of heart
disease and diagnostic
testing considering gender
differences.

Women have been observed
to have more tendencies
towards diastolic heart
failure as opposed to systolic
heart failure.
Women with CHD are
generally about 10 years
older than men at the time of
presentation which carries a
greater burden of risk
factors.
Women are less likely than
men to have typical angina
(28% verses 55%)
Silent myocardial infarctions
were illustrated to be
significantly higher in
younger women than men
(42% verses 30.7%).
Incidence was noted to be
higher in younger women
then older women (41%
verses 24%)
A higher fraction of sudden
deaths in women verses men
occurred in the absence of
prior CHD (63% verses
44%)
Many of the diagnostic
testing statistics were
considered by the authors to
be less than accurate due to
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Tamis-Holland, J., Lu, J.,
Bittner, V., Magee, M, Lopes,
N., Adler, D., et al. (2011).
Sex, Clinical Symptoms, and
Angiographic Findings in
Patients With Diabetes
Mellitus and Coronary Artery
Disease (from the Bypass
Angioplasty
Revascularization
Investigation [BARI]
2Diabetes Trial). American
Journal of Cardiology, 107,
980-985.

Worrall-Carter, L., Ski, C.,
Scruth, E., Campbell, M. &
Page, K. (2011). Systematic
Review of Cardiovascular
Disease in Women: Assessing
the Risk. Nursing Health and
Sciences, 13, 529.535.
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This study was of
observational design of the
results concerning the
BARI (2D) study.

2,368 patients from
49 clinical sites were
enrolled over a
period of 50 months.

The purpose of this study
was to determine the
relationship between
symptoms and extent of
CAD in patients with type
2 diabetes mellitus and
known CAD enrolled in
the Bypass Angioplasty
Revascularization
Investigation 2 Diabetes
trial.

Inclusion criteria
was type 2 DM,
documented CAD
involving >1
coronary vessel
treatable and no
previous
cardiovascular
treatment
interventions or
documented or
known kidney
disease.

Systemic review using
primary, secondary
randomized and controlled
studies
The purpose of the review
was to examine the
cardiovascular disease risk
in women to increase
awareness of sex specific
symptoms presentation,
and risk factors to improve
clinical outcomes.

Women >18 years of
age with at least one
newly diagnosed or
existing
cardiovascular risk
factor

Baseline angiographies
were assessed locally at
clinical sites and sent to
centralized core
laboratory where it is
analyzed for use in this
study.
Interpretation for
inclusions in the study
excluded 546 patients
who were determined
to not meet criteria.

the underrepresentation by
women as well as the older
age of then women who
were included.
Of the remaining 1,775
patients examined, 533 were
women (representing 30% of
total population inclusion).
Women had less severe and
significant CAD and less
likely to have severe disease
on coronary arteriogram as
defined by multiple diseased
LV regions (women vs men
0.59, p <0.0001)
Women vs men with
significant occluded lesions
on angiography 29% vs
42%, p<0.001,
Atypical symptomatic
presentation: atypical angina
71% vs 58% p<0.001,
Nausea 24% vs 11%
p<0.001
INTERHEART study
identified highest risk factors
for myocardial infarction in
women as diabetes mellitus
and hypertension. It also
identified
hypertriglyceridemia as a
known independent risk
factor in women.
Smoking was associated
with a greater risk of AMI
among women <45 years of
age. The INTERHEART
study concluded that 29% of
AMI were a byproduct of
smoking.
DM was identified as having
the greatest sex difference
for developing CVD.
Women with diabetes had a
3-4 fold increased risk of
developing CVD.
Most CVD risks in women
are modifiable. A study by
the Nurses Health Study
concluded that women were
able to decrease their risk of
developing CVD by
eliminating their modifiable
risk factors and maintaining
a moderate healthy lifestyle.
Women we
underrepresented in CVD
prevention and treatment
trails or sex differences were
not accounted for. The mean
percentage of women
enrolled in these trials was
30% while only one-third of
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Matthew, K., Crawford, S.,
Chae, C., Everson-Rose, S.,
Sowers, M., Sternfield, B., et
al. (2009) Are Changes in
Cardiovascular Disease Risk
Factors in Midlife Women
Due to Chronological Aging
or Menopausal Transition?
Journal of the American
College of Cardiology,
54(25), 2366-2373.

Miller,V. & Best, P. (2009).
Sex Differences in
Cardiovascular Disease.
Cardiovascular Disease, 9(3):
21-28.

Longitudinal study over a
timeframe of 10 years to
examine whether changes
in traditional and oval
coronary heart disease risk
factors are greater within a
year of the final menstrual
period, relative changes
that occur before or after
that interval, in a
multiethnic cohort.

Exploratory design intent
on building groundwork of
understanding the gender
specific pathophysiology
of cardiovascular disease
in order to construct a risk
assessment and treatment
course tailored for women.
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1054 women who
had their FMP by the
end of 9 years of
follow up in SWAN
( a longitudinal
multisite,
community based
study)

The SWAN
participants were
questioned annually
about health, lifestyle,
and psychological
factors.
Anthropometric
measurements and
fasting blood draws
were obtained at early
follicular phase of the
menstrual cycle at
specific time intervals
to allow a standardized
hormonal milieu.
The groups were
divided into three time
periods relative to FMP
and the analytic sample
was compared using
chi-square and t tests.
Effects of sex steroids
on the factors
contributing to
cardiovascular disease
were reviewed.
Determine the
participation rate in
women in ongoing
studies of CVD and
how the representation
of women are
adequately or
inadequate in current
ongoing research.

trials reported results by
gender. This leads to
treatment recommendations
tailored towards results from
a predominantly male
population.
Increases in total cholesterol
and LDL were substantial
around time of FMP
No difference was noted
within ethnicity and these
changes only in baseline
weight measurements
The analysis shows no
influence of FMP on blood
pressure, insulin, glucose or
inflammatory factors

The proposed hypothesis
shows validated assessment
tool specific for women
which incorporates
information and history
about pregnancy,
reproductive history, and
hormone exposure, might
improve cardiovascular risk
stratification for targeting
early intervention in women
as they age.
CVD falls into 3 general
categories with regard to sex
disparity: 1) conditions
unique to one sex, 2)
conditions which occur in
both sexes but have unique
presentations in each sex, 3)
those which have disparate
prevalence rates yet occur in
both genders.
Sex steroids affect all
components of the vascular
wall, heart, as well as blood
elements which come in
contact with luminal
surfaces.

Finks, S. (2010).
Cardiovascular Disease in
Women. Cardiology, 7, 179199.

The design of this study is
of action research design.
The purpose of this
research was using both
literature review, applying
evidence based treatment
guidelines and designing
an optimal treatment
options.

An estimated 66,000 more
women than men die after
acute myocardial infarction
and intervention. Women
also experience a higher
mortality rate and poorer
outcomes then men.
Inflammatory markers
indicating risk for CVD such
as C-reactive protein
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(hsCRP) are higher at
baseline in women than men.
Women with diabetes are 37 times more at risk for
developing or dying of CVD
then women without
diabetes.
Premenopausal women have
lower LDL and higher HDL
levels then men whereas
postmenopausal women
experience elevated levels of
LDL cholesterol and HDL
levels continue to decline.
A meta-analysis revealed a
37% increased risk of CVD
events in women with higher
concentrations of
triglycerides then that in
men which showed a 14%
increased risk.

Mosca, L., Manson, J.,
Sutherland, S., Langer, R.,
Manolio, T., & BarrettConner, E. (2009).
Cardiovascular Disease in
Women : A Statement for
Healthcare Professionals
From the American Heart
Association. Circulation.
Retrieved March 17, 2013
from
www.circ.ahajournals.org/con
tent/96/7/2468.full

Cross-sectional design
study conducted to
determine the public
awareness and knowledge
of CVD as well as risk
factor awareness as well as
primary, secondary and
tertiary prevention
strategies.

Descriptive statistics of
respondents
characteristics,
awareness, and
preventative barriers
were conducted to
present the findings in
relations to population
proportions

Hypertension in women is
associated with a 2.5 higher
risk of cardiovascular death,
MI, stroke and heart failure
in women compared to a 1.6
increased risk in men with
the same hypertension
parameters.
In evaluation of knowledge
and awareness of leading
cause of death among
women, 55% correctly
identified heart disease as
the leading cause of death
compared to 30% in 1997.
81% answered they had
read, seen, or heard
information regarding heart
disease in the past 12
months.
Tobacco use is attributed to
50% of myocardial
infarctions among middle
aged women.
Approximately half of all
deaths in persons with noninsulin dependent diabetes
mellitus are due to heart
disease.
Hormone replacement
therapy may indicate false
ST depression.
A meta analysis
demonstrated a reduction of
a second vascular event of
25 % by using aspirin
therapy.
Lipid lowering therapy
provides beneficial therapy
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in women by decreasing
hyperlipidemia and reducing
mortality of women with
CHD by >50%.
Women were found to be
less likely to enroll in
rehabilitation then men
(6.9% vs 13.3%)
Women were less likely to
undergo bypass surgery
(20.4% vs 24.6%) then men.

Walsh, J. & Pignone, M.
(2004). Drug Treatment of
Hyperlipidemia in Women.
American Medical
Association, 291,(18); 22432252.

Xhyheri, B. & Bugiardini, R.
(2010). Diagnosis and
Treatment of Heart Disease;
Are Women Different From
Men? Progress in
Cardiovascular Disease, 53,
227-236.

Literature review including
13 studies
Studies that including
gender differences,
treatment duration of at
least a year,

Literature review design
which reviews current
diagnostic and treatment
options in reference to
gender differences.

6 trials included
11435 women
without CVD and
using lipid lowering
medications
8 trials included
8272 women with
CVD and assessed
the effects of lipid
lowering
medications

MEDLINE database
was used
Inclusions were 1)
randomized clinical
trials of outpatients
with or without CVD,
2) treatment duration of
at least a year, 3)
classified the study as
either primary ( without
prior CVD) or
secondary ( known
CVD), 4) Provided data
on women and the
effect of lipid-lowing
drug therapy

Incidence of stroke is higher
in men (19%) then women,
although women are more
likely to die from a vascular
occurrence (16% vs 8%).
Use of lipid-lowering
medications in women
without CVD, there was a
possible reduction in CHD
events (RR, 0.80; 95% CI,
0.71 – 0.91) but not
mortality. (RR, 0.95; 95%CI,
0.62 – 1.46)
In women with known CVD
or at high risk, use of
antihyperlipidemia
medications showed a
reduction in CHD events and
CHD associated mortality.
(RR 0.74;95% CI, 0.62-1.68)
Aspirin therapy for CVD
affects women differently
than men. While it is more
effective in preventing an
MI in men (32%), it is more
beneficial in preventing a
stroke in women (17%).
There is a lower level of
preventative treatment of
therapy in use of statins in
women than men.
Although the available
literature concerning the use
of ACE inhibitors in women
in minimal, the research that
is available shows a lower
rate of effectiveness in
women (22%) then men
(37%) concerning recovery
from a MI and treatment for
CHF.
The benefit of the use
concerning clopidogrel in
treatment following a CVD
event was lower in women
(7%) then in men (16%)
while the risk of bleeding
from the use of clopidogrel
was greater in women (43%)
then in men (22%)
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The benefits of B-blockers
were shown in some trials to
be more effective in women
(31%) then in men (5%)
Ahmed, W., Tully, P., Knight,
J. & Baker, R. (2011). Female
Sex as an Independent
Predictor of Morbidity and
Survival After Isolated
Coronary Artery Bypass
Grafting. The Annuls of
Thoracic Surgery, 92(1); 5967.

Case study design that
sought to determine
whether female sex was an
independent risk factor for
combined in-hospital
morbidity, mortality, and
long term survival after
coronary artery bypass
grafting (CABG).

Data was collected
for 1,114 women
and 3,628 men who
underwent coronary
bypass grafting
between January 1
1996 and December
31 2004 with a
median follow up of
7.9 years.

Surgical coronary
artery bypass grafting
and in hospital
rehabilitation

The female sex was
associated with being an
increased risk factor in
undergoing a CABG
(adjusted odds ratio 1.29;
95% CI, 1.04 to 1.59, p =
0.02). Adjusted survival
mode showed female sex
was associated with cardiac
mortality (hazard ratio 1.28;
95% CI, 0.96 to 1.73; p =
0.10)
Females were older with
lower body surface area and
more significant comorbid
conditions then did males
(p<0.05)
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